DK167650B1 - Anvendelse af erythropoietin til fremstilling af et laegemiddel mod jernoverskudsrelaterende lidelser - Google Patents

Anvendelse af erythropoietin til fremstilling af et laegemiddel mod jernoverskudsrelaterende lidelser Download PDF

Info

Publication number
DK167650B1
DK167650B1 DK407488A DK407488A DK167650B1 DK 167650 B1 DK167650 B1 DK 167650B1 DK 407488 A DK407488 A DK 407488A DK 407488 A DK407488 A DK 407488A DK 167650 B1 DK167650 B1 DK 167650B1
Authority
DK
Denmark
Prior art keywords
iron
erythropoietin
red blood
excess
serum
Prior art date
Application number
DK407488A
Other languages
Danish (da)
English (en)
Other versions
DK407488D0 (da
DK407488A (da
Inventor
John W Adamson
Joseph W Eschbach
Michael R Downing
Joan C Egrie
Original Assignee
Kirin Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kirin Amgen Inc filed Critical Kirin Amgen Inc
Publication of DK407488D0 publication Critical patent/DK407488D0/da
Publication of DK407488A publication Critical patent/DK407488A/da
Application granted granted Critical
Publication of DK167650B1 publication Critical patent/DK167650B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Treatment Of Water By Oxidation Or Reduction (AREA)
  • Manufacture Of Iron (AREA)
  • Chemical Treatment Of Metals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Treatment Of Water By Ion Exchange (AREA)
  • Peptides Or Proteins (AREA)
  • Compounds Of Iron (AREA)
  • Hydrogen, Water And Hydrids (AREA)
DK407488A 1986-11-21 1988-07-21 Anvendelse af erythropoietin til fremstilling af et laegemiddel mod jernoverskudsrelaterende lidelser DK167650B1 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US06/933,495 US5013718A (en) 1986-11-21 1986-11-21 Method for treating iron overload using EPO
US93349586 1986-11-21
PCT/US1987/002673 WO1988003808A1 (en) 1986-11-21 1987-10-19 Method for treating iron overload
US8702673 1987-10-19

Publications (3)

Publication Number Publication Date
DK407488D0 DK407488D0 (da) 1988-07-21
DK407488A DK407488A (da) 1988-07-21
DK167650B1 true DK167650B1 (da) 1993-12-06

Family

ID=25464076

Family Applications (1)

Application Number Title Priority Date Filing Date
DK407488A DK167650B1 (da) 1986-11-21 1988-07-21 Anvendelse af erythropoietin til fremstilling af et laegemiddel mod jernoverskudsrelaterende lidelser

Country Status (16)

Country Link
US (1) US5013718A (es)
EP (1) EP0269394B1 (es)
JP (1) JPH0692316B2 (es)
KR (1) KR950009100B1 (es)
AT (1) ATE68352T1 (es)
AU (1) AU602028B2 (es)
CA (1) CA1322165C (es)
DE (1) DE3773852D1 (es)
DK (1) DK167650B1 (es)
ES (1) ES2039252T3 (es)
GR (1) GR3003254T3 (es)
IE (1) IE60865B1 (es)
IL (1) IL84275A (es)
NZ (1) NZ222432A (es)
PT (1) PT86187B (es)
WO (1) WO1988003808A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR880012235A (ko) * 1987-04-10 1988-11-26 벤자민 에프.람버트 정상 포유동물의 헤마토크릿을 증가시키는 방법
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US6012450A (en) * 1993-01-29 2000-01-11 Aradigm Corporation Intrapulmonary delivery of hematopoietic drug
US5354934A (en) * 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
WO1996014081A1 (en) * 1994-11-03 1996-05-17 Boehringer Mannheim Gmbh Use of erythropoietin in the treatment of rheumatoid arthritis
WO1996030068A1 (en) 1995-03-31 1996-10-03 Aradigm Corporation Intrapulmonary delivery of hematopoietic drug
TW586933B (en) * 1996-06-20 2004-05-11 Chugai Pharmaceutical Co Ltd Compositions for treating liver-complaints using EPO
US5952226A (en) * 1996-11-05 1999-09-14 Modex Therapeutiques Hypoxia responsive EPO producing cells
AR019025A1 (es) 1998-04-09 2001-12-26 Roche Diagnostics Gmbh Uso de eritropoyetina en bajas dosis para producir un preparado farmaceutico para el tratamiento de hemocromatosis, preparado farmaceutico combinadoutilizado segun dicho uso y envase farmaceutico unitario que contiene al referido preparado farmaceutico combinado
EP0965349A1 (de) * 1998-06-18 1999-12-22 Roche Diagnostics GmbH Verwendung von Erythropoietin zur Behandlung von Hämochromatosen
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
DE19857609A1 (de) * 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
WO2001035095A2 (en) * 1999-11-12 2001-05-17 Rothenberg Barry E Diagnostic test for hemochromatosis
US7160855B2 (en) * 2002-03-14 2007-01-09 Children's Hospital & Research Center At Oakland Enhancement of iron chelation therapy
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
US7611700B2 (en) * 2002-09-09 2009-11-03 Hanall Pharmaceuticals, Co., Ltd. Protease resistant modified interferon alpha polypeptides
JP2010510794A (ja) 2006-11-28 2010-04-08 ハナル ファーマシューティカル カンパニー リミテッド 修飾型エリスロポエチンポリペプチド及びこの治療用用途
US10694961B2 (en) 2011-06-13 2020-06-30 Cedaris-Sinai Medical Center Assessment of iron deposition post myocardial infarction as a marker of myocardial hemorrhage
US10694962B2 (en) 2011-06-13 2020-06-30 Cedars-Sinai Medical Center Assessment of iron deposition post myocardial infarction as a marker of myocardial hemorrhage
FR3037592B1 (fr) 2015-06-18 2017-06-09 Michelin & Cie Pneumatique pourvu d'une bande de roulement comprenant un elastomere dienique et un systeme d'elastomeres thermoplastiques

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0686480B2 (ja) * 1983-02-21 1994-11-02 雪印乳業株式会社 エリスロポエチン製造用モノクローナル抗体
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
US4667016A (en) * 1985-06-20 1987-05-19 Kirin-Amgen, Inc. Erythropoietin purification

Also Published As

Publication number Publication date
DE3773852D1 (de) 1991-11-21
IL84275A (en) 1993-04-04
ES2039252T3 (es) 1993-09-16
IE873113L (en) 1988-05-21
ATE68352T1 (de) 1991-11-15
EP0269394B1 (en) 1991-10-16
WO1988003808A1 (en) 1988-06-02
US5013718A (en) 1991-05-07
PT86187A (en) 1987-12-01
IE60865B1 (en) 1994-08-24
DK407488D0 (da) 1988-07-21
DK407488A (da) 1988-07-21
EP0269394A2 (en) 1988-06-01
NZ222432A (en) 1990-07-26
GR3003254T3 (en) 1993-02-17
KR950009100B1 (ko) 1995-08-14
AU602028B2 (en) 1990-09-27
KR890700032A (ko) 1989-03-02
PT86187B (pt) 1990-11-07
EP0269394A3 (en) 1988-09-14
JPS63159322A (ja) 1988-07-02
CA1322165C (en) 1993-09-14
AU8179487A (en) 1988-06-16
JPH0692316B2 (ja) 1994-11-16

Similar Documents

Publication Publication Date Title
DK167650B1 (da) Anvendelse af erythropoietin til fremstilling af et laegemiddel mod jernoverskudsrelaterende lidelser
Clyne et al. Effect of erythropoietin treatment on physical exercise capacity and on renal function in predialytic uremic patients
Ahsan Intravenous infusion of total dose iron is superior to oral iron in treatment of anemia in peritoneal dialysis patients: a single center comparative study.
US7541333B2 (en) Angiogenically effective unit dose of FGF-2 and method of use
Akizawa et al. Clinical effect of recombinant human erythropoietin on anemia associated with chronic renal failure. A multiinstitutional study in Japan
Lim et al. The safety and the efficacy of maintenance therapy of recombinant human erythropoietin in patients with renal insufficiency
Åkesson et al. Visceral improvement following combined plasmapheresis and immunosuppressive drug therapy in progressive systemic sclerosis
JP2858752B2 (ja) 正常な哺乳動物のヘマトクリツト値の増大方法
Spearing et al. Long-term self-administered subcutaneous heparin in pregnancy.
Eidemak et al. Intravenous versus subcutaneous administration of recombinant human erythropoietin in patients on haemodialysis and CAPD
Sobota Recombinant human erythropoietin in patients with anemia due to end-stage renal disease
Schaefer et al. Treatment of the anemia of hemodialysis patients with recombinant human erythropoietin
Faris Use of recombinant human erythropoietin in the perioperative period of orthopedic surgery
Navarro et al. Effectiveness of intravenous administration of Fe-gluconate-Na complex to maintain adequate body iron stores in hemodialysis patients
Landolfi et al. Meningeal hematopoiesis causing exophthalmus and hemiparesis in myelofibrosis: Effect of radiotherapy: A case report
Kaboth et al. Advantages of isovolemic large‐volume erythrocytapheresis as a rapidly effective and long‐lasting treatment modality for red blood cell depletion in patients with polycythemia vera
Jindal et al. Low-dose subcutaneous erythropoietin corrects the anaemia of renal transplant failure
Zehnder et al. Human recombinant erythropoietin in anaemic patients on maintenance haemodialysis. Secondary effects of the increase of haemoglobin
Disch et al. Intravenous Iloprost treatment for severe bone pain caused by sickle cell crisis
Thibonnier et al. Comparative trial of labetalol and acebutolol, alone or associated with dihydralazine, in treatment of essential hypertension.
Heckmann et al. Guillain-Barre syndrome in association with focal segmental glomeruloslcerosis
Gottstein Evaluation of isovolemic hemodilution
Stegmayr Better response to sc erythropoietin in CAPD than HD patients
Tanakay et al. Multicenter study with recombinant human erythropoietin
Lundin Recombinant erythropoietin and chronic renal failure

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PUP Patent expired